Amifostine before chemotherapy: Improved tolerance profile of the subcutaneous over the intravenous route

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3288-3293

  Koukourakis, Michael I ^a   Simopoulos, Costantinos ^a   Minopoulos, George ^a   Patlakas, George ^a   Polychronidis, Alexandros ^a   Limberis, Vassilis ^a   Romanides, Kostantinos ^a   Pitiacoudis, Michael ^a   Manolas, Costantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHYLPREDNISOLONE SODIUM SUCCINATE; RANITIDINE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROTECTION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; INJECTION PAIN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; SEPSIS; SKIN MANIFESTATION; STOMACH CANCER; VOMITING;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; VOMITING;

EID: 0041833715     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., and Glick, J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J. Clin. Oncol., 14: 2101-2112, 1996.
2. Brizel, D. M., Wasserman, T. H., Henke, M., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., Russell, L., Oster, W., and Sauer, R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol., 18: 3339-3345, 2000.
3. Koukourakis, M. I. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs, 13: 181-209, 2002.
4. Koukourakis, M. I., Kyrias, G., Kakolyris, S., Kouroussis, C., Frangiadaki, C., Giatromanolaki, A., Retalis, G., and Georgoulias, V. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J. Clin. Oncol., 18: 2226-2233, 2000.
5. Anne, P., Curran, W., Machtay, M., Rosenthal, D., Brizel, D., Irwin, D., Chougule, P., Estopinal, N., Berson, A., and Morrison, W. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer (WR-B060). Proc. Am. Soc. Ther. Radiol. Oncol. (ASTRO), 43th annual meeting, Abstr. 150.
6. WHO. Handbook for reporting results of cancer treatment. Geneva: WHO, 1979.
7. Bourhis, J., De Crevoisier, R., Abdulkarim, B., Deutsch, E., Lusinchi, A., Luboinski, B., Wibault, P., and Eschwege, F. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 46: 1105-1108, 2000.
8. Abitbol, A., Lewin, A., Rodrigues, M. A., Wolfsoy, A., Markoe, A., Sridhar, K., Hamilton-Nelson, K., Goodwin, J. Sequential trial of concurrent hyperfractionated radiation therapy and 5-fluorouracil, cisplatin and paclitaxel with and without amifostine in patients with locally advanced head and neck squamous cell carcinoma. Proc. Am. Soc. Clin. Oncol., 20: 228a, 2001.
9. Antonadou, D., Pepelassi, M., Synodinou, M., Puglisi, M., and Throuvalas, N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 52: 739-747, 2002.
10. Antonadou, D., Coliarakis, N., Synodinou, M., Athanassiou, H., Kouveli, A., Verigos, C., Georgakopoulos, G., Panoussaki, K., Karageorgis, P., and Throuvalas, N. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced stage lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 51: 915-922, 2001.
11. Komaki, R., Lee, J. S., Kaplan, B., Allen, P., Kelly, J. F., Liao, Z., Stevens, C. W., Fossella, F. V., Zinner, R. G., and Papadimitrakopoulou, V. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 20: 325a, 2001.
12. Bafaloukos, D., Samelis, G., Mela, A., Aravantinos, G., Xiros, N., Dimou, M., Kalofonos, H. P., Samantas, E., Retalis, G., and Papakostas, P. Use of amifostine to reduce toxicity following taxol-based chemotherapy in solid tumors. A randomized phase II study of the Hellenic Cooperative Group. Proc ECCO 11. Eur. J. Cancer 37 (Suppl. 6, Abstr. 1289): 347, 2001.
13. Shaw, L., Brown, W., Schein, P., Stogniew, M. A phase I study comparing bioavailability of intravenous and subcutaneous administration of amifostine (Ethyol). Proc. Am. Soc. Clin. Oncol., 16: 250a, 1997.
14. Shaw, L. M., Turrisi, A. T., Glover, D. J., Bonner, H. S., Norfleet, A. L., Weiler, C., and Kligerman, M. Human pharmacokinetics of WR-2721. Int. J. Radiat. Oncol. Biol. Phys., 12: 1501-1504, 1986.
15. Cassat, D. R., Fazenbaker, A., Kifle, G., and Bachy, C. M. Preclinical studies on the radioprotective efficacy and pharmacokincties of subcutaneously administered amifostine. Semin. Oncol. 29 (Suppl. 19): 2-8, 2002.
16. Cassatt, D. R. Extended window of mucosal radioprotection with intravenous or subcutaneous amifostine in rats. Proc. Am. Soc. Clin. Oncol., 20: 279a, 2001.
17. Bonner, H. S., and Shaw, L. M. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J. Clin. Pharmacol., 42: 166-174, 2002.
18. Koukourakis, M. I., Romanidis, K., Froudarakis, M., Kyrgias, G., Koukourakis, G. V., Retalis, G., and Bahlitzanakis, N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br. J. Cancer, 87: 385-392, 2002.
19. Vamvakas, L., Kakolyris, S., Kouroussis, C., Kandilis, K., Mavroudis, D., Ziras, N., Androulakis, N., Kalbakis, K., Sarra, E., Souglakos, J., and Georgoulias, V. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am. J. Clin. Oncol., 25: 65-70, 2002.
20. Ohtsu, A., Boku, N., Yoshioka, T., Hyodo, I., Shirao, K., Shimada, Y., Saitoh, S., Nakamura, A., Yamamichi, N., Yamamoto, S., Yoshida, S. A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma. Jpn. J. Clin. Oncol., 33: 28-32, 2003.